SEC Filings
Rezolute Prices $100 Million Offering At $3.87 To Fund Ersodetug Launch Preparation
New common shares account for about 19% of post-offering shares as the company prepares for regulatory discussions.
Rezolute (RZLT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
New common shares account for about 19% of post-offering shares as the company prepares for regulatory discussions.
SEC Filings
The company expects about $93.5 million after offering costs as preliminary ersodetug study findings await complete analysis.
SEC Filings
The ownership report dates to September 30, while Rezolute separately priced financing expected to bring about $100 million in gross proceeds.
Markets
The rare-disease drug developer also priced approximately $100 million in financing for commercialization preparations and other costs.
SEC Filings
Twelve participants stopped intravenous glucose entirely; Rezolute expects the completed-study analysis by mid-December 2026.
SEC Filings
The quarterly loss widened to $18.5 million, while Rezolute plans approval applications for one or potentially both indications in 2027.
SEC Filings
The company's investor deck puts the U.S. opportunity for ersodetug at about 6,000 patients, driven by weight-based dosing.
SEC Filings
The New York investment adviser holds 5,332,068 shares of the rare-disease drug developer, with an event date of September 30.
SEC Filings
The annual proxy lists Nevan Elam as CEO and acting chairman, with a vote on more authorized shares set for December 2.
SEC Filings
The ersodetug trial needs a response rate of at least 56% among 16 participants to clear its statistical bar.
SEC Filings
The agency made its recommendation despite a trial that missed its primary and key secondary endpoints, and it declined to comment on approvability.